HOUSTON--(BUSINESS WIRE)--Lipid Labs, Inc. (Pink Sheets:LPDL) signed a nationwide marketing agreement with SpectraCell Corporation to market the Lipoprotein Particle Profile Screening product to the medical industry. This test provides doctors with a superior diagnostic tool for determining patient risk related to blood cholesterol. This technology was sold to SpectraCell by Lipid Labs in 2006. The test was the first major diagnostic tool commercialized by Lipid Labs.
